Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

RGNX
REGENXBIO Inc.
stock NASDAQ

At Close
Jan 28, 2026 3:59:52 PM EST
11.01USD-17.897%(-2.40)4,987,432
10.80Bid   11.01Ask   0.21Spread
Pre-market
Jan 28, 2026 9:28:36 AM EST
9.51USD-29.083%(-3.90)461,216
After-hours
Jan 28, 2026 4:45:30 PM EST
11.20USD+1.683%(+0.19)5,429
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
07:05AM EST  REGENXBIO Announces Presentations at the 18th Annual WORLDSymposium(tm) 2022   PR Newswire
Jan 28, 2022
09:25AM EST  Expert Ratings For Regenxbio   Benzinga
06:30AM EST  SVB Leerink Maintains Market Perform on Regenxbio, Lowers Price Target to $35   Benzinga
Jan 10, 2022
07:07AM EST  REGENXBIO Announces Initiation Of Second Pivotal Trial In RGX-314 Clinical Program For The Treatment Of Wet AMD Using Subretinal Delivery   Benzinga
07:06AM EST  REGENXBIO Announces Initiation of Second Pivotal Trial in RGX-314 Clinical   PR Newswire
Jan 6, 2022
07:15AM EST  REGENXBIO Announces FDA Clearance Of IND For Clinical Trial Of RGX-202   RTTNews
07:08AM EST  REGENXBIO Announces FDA Clearance Of IND For Clinical Trial Of RGX-202, A Novel Gene Therapy Candidate For Duchenne Muscular Dystrophy   Benzinga
07:05AM EST  REGENXBIO Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel   PR Newswire
Dec 15, 2021
04:30PM EST  16:29 Wednesday, December 15, 2021Wedbush (RTTNews) - Wedbush Starts Regenxbio Inc (RGNX) At Neutral With $29 Price Target   RTTNews
10:05AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021   Benzinga
07:10AM EST  Wedbush Initiates Coverage On Regenxbio with Neutral Rating, Announces Price Target of $29   Benzinga
Nov 22, 2021
11:15AM EST  RegenXbio's Duchenne Gene Therapy Secures FDA Orphan Drug Tag   Benzinga
07:37AM EST  REGENXBIO Gets FDA's Orphan Drug Designation For RGX-202   RTTNews
07:08AM EST  REGENXBIO: FDA Grants Orphan Drug Designation For RGX-202 For Duchenne Muscular Dystrophy   RTTNews
07:04AM EST  REGENXBIO Granted Orphan Drug Designation for RGX-202, a Potential One-Time Gene Therapy for the Treatment of Duchenne Muscular Dystrophy   Benzinga
07:01AM EST  REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene   PR Newswire
Nov 15, 2021
09:54AM EST  REGENXBIO Presents Additional Interim Data From Trials Of RGX-314 In Wet AMD And Diabetic Retinopathy Using Suprachoroidal Delivery At AAO 2021   Benzinga
Nov 12, 2021
04:32PM EST  REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in   PR Newswire
07:47AM EST  The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares   Benzinga
Nov 9, 2021
04:06PM EST  REGENXBIO Announces Closing of Eye Care Collaboration Agreement with AbbVie   PR Newswire
10:49AM EST  Regenxbio Muscular Dystrophy Treatment Gets Orphan Drug Designation   Benzinga
Nov 8, 2021
08:29AM EST  The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More   Benzinga
07:01AM EST  REGENXBIO to Participate in Upcoming Investor Conferences   PR Newswire
Nov 6, 2021
03:20PM EDT  Barron's Latest Picks And Pans: Alleghany, Blade Air Mobility, Gene Therapy Picks And More   Benzinga
Nov 5, 2021
07:01AM EDT  REGENXBIO Announces RGX-314 Data Presentation at the American Academy of   PR Newswire
Nov 3, 2021
09:16AM EDT  Chardan Capital Maintains Buy on Regenxbio, Lowers Price Target to $90   Benzinga
09:11AM EDT  SVB Leerink Maintains Market Perform on Regenxbio, Lowers Price Target to $43   Benzinga
Nov 2, 2021
04:28PM EDT  Regenxbio Q3 EPS $(1.37) Misses $(1.08) Estimate, Sales $30.77M Miss $41.46M Estimate   Benzinga
04:06PM EDT  REGENXBIO Reports Third Quarter 2021 Financial Results and Operational   PR Newswire
10:54AM EDT  The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US   Benzinga
10:41AM EDT  Earnings Scheduled For November 2, 2021   Benzinga
07:30AM EDT  - Draft white paper published today by the Pathway Development Consortium provides a framework for applying the accelerated approval pathway to AAV gene therapy development -   GlobeNewswire Inc
Nov 1, 2021
11:01AM EDT  Earnings Outlook For Regenxbio   Benzinga
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 26, 2021
04:06PM EDT  REGENXBIO to Host Conference Call on November 2 to Discuss Third Quarter 2021   PR Newswire
Oct 11, 2021
01:25PM EDT  Regenxbio Reveals Interim Data From Diabetic Retinopathy Gene Therapy Trial   Benzinga
09:59AM EDT  REGENXBIO Saturday Morning Highlighted Presentation Of Initial Data From Phase 2 ALTITUDE Trial Of RGX-314 For Treatment Of Diabetic Retinopathy Using Suprachoroidal Delivery At American Society Of Retina Specialists Meeting   Benzinga
Oct 10, 2021
11:59AM EDT  The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage   Benzinga
Oct 9, 2021
11:23AM EDT  RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting   PR Newswire
Oct 3, 2021
02:21PM EDT  The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs and More   Benzinga
Oct 1, 2021
03:48PM EDT  REGENXBIO Presents Initial Data from Phase II AAVIATE Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting   Benzinga
03:47PM EDT  RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting   PR Newswire
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
07:08AM EDT  REGENXBIO To Present RGX-314 Data At American Society Of Retina Specialists Annual Meeting   RTTNews
07:07AM EDT  REGENXBIO Announces RGX-314 Data Presentations At American Society Of Retina Specialists Annual Meeting Oct. 9 And 11   Benzinga
07:05AM EDT  REGENXBIO Announces RGX-314 Data Presentations at American Society of Retina   PR Newswire
Sep 27, 2021
07:15AM EDT  REGENXBIO To Present RGX-314 Data At Retina Society 54th Annual Scientific Meeting Oct. 1   Benzinga
07:05AM EDT  REGENXBIO Announces RGX-314 Data Presentations at Retina Society 54th Annual   PR Newswire
Sep 15, 2021
12:02PM EDT  Looking Into Regenxbio's Return On Capital Employed   Benzinga
Sep 14, 2021
07:24AM EDT  RBC Capital Maintains Sector Perform on Regenxbio, Raises Price Target to $55   Benzinga
06:53AM EDT  Barclays Maintains Overweight on Regenxbio, Raises Price Target to $82   Benzinga
Sep 13, 2021
01:11PM EDT  Shares of REGENXBIO Inc. (RGNX) is up over 25% on Monday morning after the company announced a collaboration deal with AbbVie to develop and commercialize RGX-314, a gene therapy candidate for the treatment of chronic retinal diseases. AbbVie will give REGENXBIO an upfront payment of $370 million.   RTTNews
10:57AM EDT  Why Regenxbio Shares Are Trading Higher Today   Benzinga
06:33AM EDT  AbbVie, REGENXBIO Form Strategic Deal, To Combine Eye Care And Gene Therapy   RTTNews
06:31AM EDT  AbbVie And REGENXBIO Announce Eye Care Collaboration; AbbVie To Pay REGENXBIO $370M Upfront Payment And Up To $1.38B In milestones   Benzinga
06:30AM EDT  AbbVie and REGENXBIO Announce Eye Care Collaboration   PR Newswire
Sep 7, 2021
04:06PM EDT  REGENXBIO to Participate in Upcoming Investor Conferences   PR Newswire
07:05AM EDT  Dr. Jean Bennett and George Migausky Join REGENXBIO Board of Directors   PR Newswire
Aug 9, 2021
04:30PM EDT  Regenxbio Q2 EPS $(1.36) Misses $(1.12) Estimate, Sales $22.00M Miss $29.02M Estimate   Benzinga
04:05PM EDT  REGENXBIO Reports Second Quarter 2021 Financial Results and Operational   PR Newswire
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
04:11AM EDT  Earnings Scheduled For August 9, 2021   Benzinga
Aug 8, 2021
10:11AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 2, 2021
04:06PM EDT  REGENXBIO to Host Conference Call on August 9 to Discuss Second Quarter 2021   PR Newswire
Jun 9, 2021
07:05AM EDT  REGENXBIO to Participate in Upcoming Investor Conferences   PR Newswire
May 14, 2021
02:41PM EDT  Regenxbio's Hunter Syndrome Gene Therapy Shows Efficacy Signals, Cognitive Development Up To Two Years   Benzinga
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
07:38AM EDT  Regenxbio Inc. (RGNX) said that RGX-121, a one-time gene therapy for Mucopolysaccharidosis Type II, continues to be well-tolerated with no drug-related serious adverse events, as per phase I/II trial results.   RTTNews
07:13AM EDT  REGENXBIO Says RGX-121 Continues To Be Well-tolerated With No Drug-related Serious Adverse Events   RTTNews
07:10AM EDT  REGENXBIO Highlights Presentation Of Added Positive Interim Data From Phase 1/2 Trial Of RGX-121 For Treatment Of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting   Benzinga
07:05AM EDT  RGX-121 for the Treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting   PR Newswire
May 6, 2021
04:06PM EDT  REGENXBIO to Present at Upcoming Investor Conferences   PR Newswire
May 5, 2021
04:48PM EDT  Regenxbio Q1 EPS $(1.20) Beats $(1.28) Estimate, Sales $18.90M Miss $23.23M Estimate   Benzinga
04:06PM EDT  REGENXBIO Reports First Quarter 2021 Financial Results and Operational   PR Newswire
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
04:16AM EDT  Earnings Scheduled For May 5, 2021   Benzinga
May 4, 2021
10:30AM EDT  Preview: Regenxbio's Earnings   Benzinga
Apr 28, 2021
04:06PM EDT  REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021   PR Newswire
Apr 27, 2021
04:55PM EDT  REGENXBIO Announces Presentations at the American Society of Gene and Cell   PR Newswire
Apr 21, 2021
07:05AM EDT  REGENXBIO To Present at the Chardan 5th Annual Genetic Medicines Manufacturing   PR Newswire
Apr 15, 2021
07:49AM EDT  The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split   Benzinga
Apr 14, 2021
04:15PM EDT  REGENXBIO Reports Dosing Of First Patient In Cohort 3 Of Phase 1/22 Trial Of RGX-121 For Treatment Of Mucopolysaccharidosis Type II   Benzinga
04:14PM EDT  REGENXBIO Announces Dosing of First Patient in Cohort 3 of Phase I/II Trial of   PR Newswire
Mar 8, 2021
11:04AM EST  Morgan Stanley Maintains Overweight on Regenxbio, Lowers Price Target to $62   Benzinga
Mar 2, 2021
08:01AM EST  The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data   Benzinga
Mar 1, 2021
04:58PM EST  Recap: Regenxbio Q4 Earnings   Benzinga
04:14PM EST  Regenxbio Q4 EPS $(1.24) Down From $(0.72) YoY, Sales $21.45M Up From $11.77M YoY   Benzinga
04:06PM EST  REGENXBIO Reports Fourth Quarter and Full-Year 2020 Financial Results and   PR Newswire
03:51AM EST  Earnings Scheduled For March 1, 2021   Benzinga
Feb 27, 2021
09:04PM EST  The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings   Benzinga
Feb 24, 2021
04:06PM EST  REGENXBIO to Participate in Upcoming Investor Conferences   PR Newswire
Feb 22, 2021
04:06PM EST  REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and   PR Newswire
Feb 16, 2021
09:09AM EST  Regenxbio Gene Therapy Shows Treatment Benefit In Wet AMD Study   Benzinga
07:22AM EST  REGENXBIO Announces Addnl Positive Interim Phase I/IIa And Long-Term Follow-Up Data Of RGX-314 For Wet AMD   RTTNews
07:11AM EST  REGENXBIO Announces Additional Interim Phase I/IIa And Long-Term Follow-Up Data Of RGX-314 For Wet AMD   Benzinga
07:05AM EST  REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term   PR Newswire
Feb 8, 2021
02:31PM EST  REGENXBIO Highlights Presentation Of Added Interim Data From Phase 1/2 Trial Of RGX-121 For Treatment Of Mucopolysaccharidosis Type II At 17th Annual WORLDSymposium 2021   Benzinga
02:29PM EST  RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 17th Annual WORLDSymposium(tm) 2021   PR Newswire
Feb 6, 2021
12:42PM EST  The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight   Benzinga
Feb 5, 2021
07:07AM EST  EGENXBIO Announces Presentations At Angiogenesis, Exudation, And Degeneration 2021 Conference On Feb. 13   Benzinga
07:05AM EST  REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and   PR Newswire
Feb 1, 2021
07:05AM EST  REGENXBIO Announces Presentations at the 17th Annual WORLDSymposium(tm) 2021   PR Newswire
Jan 19, 2021
09:50AM EST  Morgan Stanley Maintains Overweight on Regenxbio, Raises Price Target to $67   Benzinga
Jan 12, 2021
04:06PM EST  REGENXBIO Announces Closing Of Public Offering Of Common Stock And Full   PR Newswire
Jan 11, 2021
07:06AM EST  REGENXBIO to Present at the 39th Annual J.P. Morgan Healthcare Conference   PR Newswire
Jan 8, 2021
07:09AM EST  REGENXBIO Prices Public Offering Of 4.26 Mln Shares At $47.00/shr   RTTNews
07:06AM EST  REGENXBIO Prices 4.26M Share Common Stock Offering At $47/Share   Benzinga
07:05AM EST  REGENXBIO Announces Pricing Of Public Offering Of Common Stock   PR Newswire
Jan 6, 2021
04:03PM EST  REGENXBIO Announces Proposed Public Offering Of Common Stock   RTTNews
04:02PM EST  REGENXBIO Announces Proposed $175M Public Offering Of Common Stock   Benzinga
04:01PM EST  REGENXBIO Announces Proposed Public Offering Of Common Stock   PR Newswire
10:14AM EST  Benzinga's Top Upgrades, Downgrades For January 6, 2021   Benzinga
08:19AM EST  10 Biggest Price Target Changes For Wednesday   Benzinga
08:04AM EST  Raymond James Upgrades Regenxbio to Strong Buy, Announces $60 Price Target   Benzinga
06:23AM EST  SVB Leerink Maintains Market Perform on Regenxbio, Raises Price Target to $37   Benzinga
Jan 5, 2021
04:07PM EST  REGENXBIO Says Pivotal Program For RGX-314 In Treatment Of Wet AMD Is Now Active; Co. Also Announces RGX-202 Program In Duchenne Muscular Dystrophy   Benzinga
04:06PM EST  Wet AMD and New Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy   PR Newswire
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 22, 2020
04:20PM EST  REGENXBIO Reports Deal To Monetize Portion Of Zolgensma Royalties For $200M   Benzinga
04:20PM EST  REGENXBIO Announces Agreement to Monetize Portion of Zolgensma(r) Royalties for   PR Newswire
Dec 10, 2020
07:25AM EST  REGENXBIO Announces Dosing Of First Patient In Phase II ALTITUDE Trial Of RGX-314 For Treatment Of Diabetic Retinopathy Using Suprachoroidal Delivery   Benzinga
07:21AM EST  REGENXBIO Announces Dosing Of First Patient In Phase II ALTITUDE Trial Of RGX-314   RTTNews
07:05AM EST  RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery   PR Newswire
Dec 9, 2020
07:17AM EST  REGENXBIO Announces Positive Interim Data And Update For Phase I/II Trial Of RGX-121 For Mucopolysaccharidosis Type II   RTTNews
07:09AM EST  REGENXBIO Announces Positive Interim Data and Update for Phase I/II Trial of RGX-121 for the Treatment of MPS II   Benzinga
07:05AM EST  REGENXBIO Announces Positive Interim Data and Update for Phase I/II Trial of   PR Newswire
Dec 1, 2020
07:10AM EST  REGENXBIO Reports Dosing Of First Patient In Phase I/II Trial Of RGX-111 For Mucopolysaccharidosis Type I   RTTNews
07:07AM EST  REGENXBIO Announces Dosing Of First Patient In Phase I/II Trial Of RGX-111 For Treatment Of Mucopolysaccharidosis Type I   Benzinga
07:05AM EST  REGENXBIO Announces Dosing of First Patient in Phase I/II Trial of RGX-111 for   PR Newswire
Nov 23, 2020
04:05PM EST  REGENXBIO to Present at Upcoming Investor Conferences   PR Newswire
Nov 13, 2020
07:40AM EST  The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations   Benzinga
Nov 11, 2020
08:17AM EST  Morgan Stanley Maintains Overweight on Regenxbio, Lowers Price Target to $51   Benzinga
Nov 10, 2020
07:01AM EST  REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020   PR Newswire
Nov 5, 2020
04:06PM EST  REGENXBIO to Present at Upcoming Investor Conferences   PR Newswire
04:05AM EST  SVB Leerink Maintains Market Perform on Regenxbio, Lowers Price Target to $31   Benzinga
Nov 4, 2020
05:27PM EST  Recap: Regenxbio Q3 Earnings   Benzinga
04:29PM EST  Regenxbio Q3 EPS $0.23 Up From $(0.94) YoY, Sales $98.91M Up From $14.70M YoY   Benzinga
04:06PM EST  REGENXBIO Reports Third Quarter 2020 Financial Results and Operational   PR Newswire
04:41AM EST  Earnings Scheduled For November 4, 2020   Benzinga
Oct 28, 2020
04:06PM EDT  REGENXBIO To Host Conference Call on November 4 to Discuss Third Quarter 2020   PR Newswire
Oct 27, 2020
07:20AM EDT  REGENXBIO To Receive $80.0M Milestone Payment From Novartis AG   Benzinga
07:01AM EDT  REGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AG   PR Newswire
Sep 30, 2020
07:05AM EDT  REGENXBIO Announces Expansion Of Clinical Development Program For RGX-121 For The Treatment Of Mucopolysaccharidosis Type II   Benzinga
07:01AM EDT  Program for RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II)   PR Newswire
Sep 25, 2020
07:01AM EDT  REGENXBIO to Participate in Upcoming Investor Conferences   PR Newswire
Sep 14, 2020
09:45AM EDT  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating REGENXBIO   PR Newswire
Sep 9, 2020
08:34AM EDT  Clearside Biomedical Licensing Partner REGENXBIO Doses First Patient In Phase 2 Gene Therapy Trial Using SCS Microinjector For Suprachoroidal Delivery   Benzinga
07:12AM EDT  REGENXBIO Doses First Patient In Phase II AAVIATE Trial Of RGX-314 For Wet AMD Using Suprachoroidal Delivery   RTTNews
07:10AM EDT  REGENXBIO Announces Dosing Of First Patient In Phase II AAVIATE Trial Of RGX-314 For The Treatment Of Wet AMD Using Suprachoroidal Delivery   Benzinga
07:05AM EDT  REGENXBIO Announces Dosing of First Patient in Phase II AAVIATE(tm) Trial of   PR Newswire
Sep 2, 2020
04:06PM EDT  REGENXBIO to Participate in Upcoming Investor Conferences   PR Newswire
Aug 25, 2020
07:12AM EDT  REGENXBIO Says FDA Clearance Of IND For Phase II Trial Of RGX-314 For Diabetic Retinopathy Using Suprachoroidal Delivery   RTTNews
07:05AM EDT  REGENXBIO Announces FDA Clearance Of IND For Phase II Trial Of RGX-314 For The Treatment Of Diabetic Retinopathy Using Suprachoroidal Delivery   Benzinga
07:01AM EDT  REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RGX-314 for the   PR Newswire
Aug 10, 2020
09:27AM EDT  Morgan Stanley Maintains Overweight on Regenxbio, Lowers Price Target to $55   Benzinga
Aug 6, 2020
04:47PM EDT  Regenxbio Q2 EPS $(0.91) Beats $(0.94) Estimate, Sales $16.57M Miss $22.07M Estimate   Benzinga
04:06PM EDT  REGENXBIO Reports Second Quarter 2020 Financial Results and Operational   PR Newswire
07:57AM EDT  The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO   Benzinga
Aug 4, 2020
07:09AM EDT  REGENXBIO Announces Additional Positive Interim Phase 1/2a Trial Update And Program Updates For RGX-314 For Treatment Of Wet AMD   Benzinga
07:01AM EDT  REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and   PR Newswire
Jul 30, 2020
04:06PM EDT  REGENXBIO To Host Conference Call on August 6 to Discuss Second Quarter 2020   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC